Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1783 results found since Jan 2013.
Vaccination against the herpes zoster virus
CONCLUSIONS: We have a safe and effective vaccine against the herpes zoster virus that allows us to protect the most vulnerable population groups against this virus.PMID:37573820 | PMC:PMC10428030 | DOI:10.1016/j.aprim.2023.102710
Source: Atencion Primaria - August 13, 2023 Category: Primary Care Authors: Jos é Javier Gómez Marco Susana Mart ín Martín Pablo Aldaz Herce Ana Pilar Javierre Miranda Coro S ánchez Hernández Source Type: research
High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate
CONCLUSION: Patients with MS who develop HZ while on DMF have high CD4+:CD8+ ratios, suggesting an imbalance of CD4+ and CD8+ cells that may put a patient at risk for developing HZ while on DMF. This result emphasizes the need for lymphocyte subset monitoring (including CD4+:CD8+ ratios) on DMF, as well as vaccination prior to DMF initiation.PMID:37572049 | DOI:10.1177/13524585231189641
Source: Herpes - August 12, 2023 Category: Infectious Diseases Authors: Alexandra Balshi Emma Saart Sarbesh Pandeya John Dempsey Ursela Baber Jacob A Sloane Source Type: research
Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database
CONCLUSIONS: mRNA COVID-19 vaccination possibly increases the risk of herpes zoster reactivation, and thus close follow-up for herpes zoster reactivation is required.PMID:37549237 | DOI:10.1093/infdis/jiad297
Source: Herpes - August 7, 2023 Category: Infectious Diseases Authors: Jin Gu Yoon Young-Eun Kim Min Joo Choi Won Suk Choi Yu Bin Seo Jaehun Jung Hak-Jun Hyun Hye Seong Eliel Nham Ji Yun Noh Joon Young Song Woo Joo Kim Dong Wook Kim Hee Jin Cheong Source Type: research
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years
CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.PMID:37541822 | DOI:10.1016/j.vaccine.2023.07.025
Source: Vaccine - August 4, 2023 Category: Allergy & Immunology Authors: David Singer Ahmed Salem Nikita Stempniewicz Siyu Ma Sara Poston Desmond Curran Source Type: research
Herpes zoster infection following SARS-CoV-2 vaccine BNT162b2
Ital J Dermatol Venerol. 2023 Aug;158(4):364-365. doi: 10.23736/S2784-8671.23.07466-2.NO ABSTRACTPMID:37539506 | DOI:10.23736/S2784-8671.23.07466-2
Source: Herpes - August 4, 2023 Category: Infectious Diseases Authors: Wanda Lauro Francesco Cillo Francesca Nastro Gabriella Fabbrocini Claudio Marasca Source Type: research
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years
CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.PMID:37541822 | DOI:10.1016/j.vaccine.2023.07.025
Source: Herpes - August 4, 2023 Category: Infectious Diseases Authors: David Singer Ahmed Salem Nikita Stempniewicz Siyu Ma Sara Poston Desmond Curran Source Type: research
Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study
CONCLUSIONS: Our study showed that SARS-CoV2 infection is associated with an increased risk of HZ in patients with IBD.PMID:37540900 | DOI:10.1093/ibd/izad162
Source: Herpes - August 4, 2023 Category: Infectious Diseases Authors: Aakash Desai Aakriti Soni Mary S Hayney Jana G Hashash Gursimran S Kochhar Francis A Farraye Freddy Caldera Source Type: research
Herpes zoster infection following SARS-CoV-2 vaccine BNT162b2
Ital J Dermatol Venerol. 2023 Aug;158(4):364-365. doi: 10.23736/S2784-8671.23.07466-2.NO ABSTRACTPMID:37539506 | DOI:10.23736/S2784-8671.23.07466-2
Source: Herpes - August 4, 2023 Category: Infectious Diseases Authors: Wanda Lauro Francesco Cillo Francesca Nastro Gabriella Fabbrocini Claudio Marasca Source Type: research
